## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, | D.C. | 20549 |  |  |
|-------------|------|-------|--|--|
|-------------|------|-------|--|--|

| OMB APP           | ROVAL     |
|-------------------|-----------|
| OMB Number:       | 3235-0287 |
| Estimated average | hurdon    |

0.5

hours per response:

| Check this box if no longer subject |
|-------------------------------------|
| Section 16. Form 4 or Form 5        |
| obligations may continue. See       |
| Instruction 1/h)                    |

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Addre<br>Agarwal Vin |               | rson          |  | Korro Bio, Inc. [ KRRO ]      |                  |                 |                                    |        |  | ationship of Reportin<br>k all applicable)                    |   |   |  |
|----------------------------------|---------------|---------------|--|-------------------------------|------------------|-----------------|------------------------------------|--------|--|---|---|---|--|
|                                  | <u></u>       |               |  |                               |                  |                 |                                    |        | 7  | Director<br>Officer (give title                               | Other   | Owner<br>(specify                                   |  |
| (Last) C/O KORRO B               | ,             | (Middle)      | 11/11                                      | e of Earliest Transa<br>/2024 | ction (N         | lonth/          | Day/Year)                          |        |  | below) Chief Fina   | below<br>ncial Officer  | ()<br>  |  |
| 60 FIRST STRE                    | EE1, 2ND FLOC | JR, SUITE 25  |  | mendment, Date of             | Origina          | l Filed         | I (Month/Day/                      | Year)  |  | vidual or Joint/Group   | Filing (Check A   | Applicable  |  |
| (Street) CAMBRIDGE               | MA            | 02141         |  |                               |                  |                 |                                    |        | Line)  |   |   |   |  |
| (City)                           | (State)       | (Zip)         |  |                               |                  |                 |                                    |        |  |   |   |   |  |
|                                  |               | Table I - Nor | n-Derivative S                             | Securities Acq                | uired,           | Dis             | posed of,                          | or Ben | eficially                                      | Owned   |   |   |  |
| 1. Title of Security (Instr. 3)  |               |               | 2. Transaction<br>Date<br>(Month/Day/Year) | Execution Date,               |                  | ction<br>Instr. | 4. Securities<br>Disposed Of<br>5) |        |  | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |  |
|                                  |               |               |  | Code                          | v                | Amount          | (A) or<br>(D)                      | Price  | Reported<br>Transaction(s)<br>(Instr. 3 and 4) |   | (Instr. 4)  |   |  |
| Common Stock                     |               |               | 11/11/2024                                 |                               | M <sup>(1)</sup> |                 | 800                                | A      | \$11.68  | 800   | D   |   |  |
| Common Stock                     |               |               | 11/11/2024                                 |                               | S <sup>(1)</sup> |                 | 800                                | D      | \$70   | 0   | D   |   |  |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of<br>Deriv | r<br>osed<br>)<br>:. 3, 4 | 6. Date Exerc<br>Expiration Da<br>(Month/Day/Y | ate                | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>(Instr. 3 ar | f<br>g<br>Security                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|---|---|--|---|------------------------------|---|-------------|---------------------------|--|--------------------|---|--|---|--|--|--|--|
|   |   |  |   | Code                         | v | (A)         | (D)                       | Date<br>Exercisable                            | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$11.68   | 11/11/2024                                 |   | M <sup>(1)</sup>             |   |             | 800                       | (2)  | 05/29/2031         | Common<br>Stock   | 800                                    | \$0   | 30,807   | D  |  |  |

## **Explanation of Responses:**

- 1. The reported transactions occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 19, 2024.
- 2. The shares subject to the option vest as to 25% of the shares on May 11, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

## Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Jeffrey Cerio, Attorney-infact

11/12/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Ram Aiyar, Jeffrey Cerio and Oliver Dolan, signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director, and/or securityholder of Korro Bio, Inc., a Delaware corporation (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents (such as Update Passphrase Authentication), to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an employee of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of November 12, 2024.

| /s/ Vineet Agarwa | l |
|-------------------|---|
| Signature         |   |
| Vineet Agarwal    |   |
| Print Name        |   |